Skip to content

David Williamson

6 papers in the library · 65 citations · publishing 2021-2025

Papers

Sort Most recent Most cited

The pattern of dissociative symptoms differs between post-traumatic stress disorder and first esketamine administration for treatment-resistant depression.

Journal of Affective Disorders June 12, 2025 David Williamson, Linda Williamson, Viola Vaccarino et al. 2 citations

Dissociative symptoms are commonly observed in a substantial minority of patients with Post-Traumatic Stress Disorder (PTSD) and during the first administration of esketamine for the treatment of Treatment-Resistant Depression (TRD). We examine differences in the number and pattern of dissociative symptoms (depersonalization, derealization, dissociative amnesia, identity fragmentation) reported...

Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues.

Expert Review of Neurotherapeutics June 1, 2025 Rosalie Girard Pepin, Fatemeh Seyfzadeh, David Williamson et al. 7 citations

Disorders of consciousness (DoC) are characterized by impaired arousal and/or awareness, ranging from coma to unresponsive wakefulness syndrome, minimally conscious state, and cognitive motor dissociation. Pharmacological treatment options remain limited, complicated by the heterogeneity of etiologies, such as traumatic brain injury, stroke, and infections. The lack of rigorous clinical trials...

Psychometric properties of the 23-Item Clinician Administered Dissociative States Scale (CADSS) in a psychological trauma population.

Journal of Affective Disorders November 1, 2024 J Douglas Bremner, David Williamson, Viola Vaccarino 5 citations

Dissociative symptoms are both a pathological consequence of exposure to psychological trauma as well as a side effect of N-methyl-d-aspartate (NMDA) receptor antagonist medications; therefore, accurate and valid assessment of these symptoms is important. The psychometric properties of the 23-item Clinician Administered Dissociative States Scale (CADSS) have been characterized in the ketamine...

Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray

Psychiatry Research March 15, 2023 Ibrahim Turkoz, J. Craig Nelson, Samuel T. Wilkinson et al. 19 citations

This exploratory post hoc analysis of two pooled 4-week, phase 3, double-blind, placebo- and active-controlled studies that compared esketamine nasal spray plus a newly initiated oral antidepressant (ESK+AD; n = 310) with a newly initiated oral AD plus placebo nasal spray (AD+PBO; n = 208) in patients with treatment-resistant depression (TRD) examined baseline patient demographic and...

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD

The International Journal of Neuropsychopharmacology December 14, 2022 David Williamson, Ibrahim Turkoz, Ewa Wajs et al. 11 citations

BACKGROUND: "Dissociation" comprises distinct phenomena, some of which are associated with esketamine treatment and some may overlap with positive symptoms of psychosis. Relationships between dissociation and psychotic symptoms assessed by -clinician report vs conventional rating scales were investigated in a post hoc analysis of data from the initial treatment session in an -open-label,...

Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response

The Journal of Clinical Psychiatry July 16, 2021 Ibrahim Turkoz, Ella Daly, Jaskaran Singh et al. 21 citations

) and treatment-resistant depression (TRD) who did not meet response criteria within the first week of treatment. The current study is a pooled post hoc analysis of two phase 3, double-blind, active-controlled studies, conducted between August 2015 and February 2018, comparing ESK + AD with an oral antidepressant plus placebo (AD + PBO). Early treatment response was defined as a ≥ 50% decrease...